File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A novel strategy to generate biologically active neo-glycosaminoglycan conjugates

TitleA novel strategy to generate biologically active neo-glycosaminoglycan conjugates
Authors
Issue Date1999
PublisherOxford University Press. The Journal's web site is located at http://glycob.oxfordjournals.org/
Citation
Glycobiology, 1999, v. 9 n. 12, p. 1331-1336 How to Cite?
AbstractHeparin and heparan sulfate are structurally related polysaccharides with a variety of biological effects/functions. Most of these effects are due to interactions, of varying specificity, between the negatively charged polysaccharide chains and proteins. While such interactions generally involve a single saccharide domain of decasaccharide size or less, ternary complexes of two protein molecules binding to separate domains on a single polysaccharide chain are known to occur. To facilitate studies on domain organization and its importance for biological function a strategy was developed to chemically conjugate defined heparin oligomers in linear and chemoselective fashion. The procedure requires that the oligosaccharide to provide the reducing-terminal domain of the conjugate is generated by lyase degradation of a parent polysaccharide, whereas the nonreducing-terminal domain is obtained through deaminative cleavage with nitrous acid. The applicability of the method was demonstrated by constructing a conjugate composed of two heparin 12-mers, of which the reducing-terminal component contained the antithrombin-binding region, whereas the nonreducing-terminal domain did not. Contrary to any of the unconjugated oligomers, the product was found to efficiently promote the inactivation of thrombin by antithrombin.
Persistent Identifierhttp://hdl.handle.net/10722/179405
ISSN
2015 Impact Factor: 3.283
2015 SCImago Journal Rankings: 1.692
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorRong, Jen_US
dc.contributor.authorNordling, Ken_US
dc.contributor.authorBjörk, Ien_US
dc.contributor.authorLindahl, Uen_US
dc.date.accessioned2012-12-19T09:56:13Z-
dc.date.available2012-12-19T09:56:13Z-
dc.date.issued1999en_US
dc.identifier.citationGlycobiology, 1999, v. 9 n. 12, p. 1331-1336en_US
dc.identifier.issn0959-6658en_US
dc.identifier.urihttp://hdl.handle.net/10722/179405-
dc.description.abstractHeparin and heparan sulfate are structurally related polysaccharides with a variety of biological effects/functions. Most of these effects are due to interactions, of varying specificity, between the negatively charged polysaccharide chains and proteins. While such interactions generally involve a single saccharide domain of decasaccharide size or less, ternary complexes of two protein molecules binding to separate domains on a single polysaccharide chain are known to occur. To facilitate studies on domain organization and its importance for biological function a strategy was developed to chemically conjugate defined heparin oligomers in linear and chemoselective fashion. The procedure requires that the oligosaccharide to provide the reducing-terminal domain of the conjugate is generated by lyase degradation of a parent polysaccharide, whereas the nonreducing-terminal domain is obtained through deaminative cleavage with nitrous acid. The applicability of the method was demonstrated by constructing a conjugate composed of two heparin 12-mers, of which the reducing-terminal component contained the antithrombin-binding region, whereas the nonreducing-terminal domain did not. Contrary to any of the unconjugated oligomers, the product was found to efficiently promote the inactivation of thrombin by antithrombin.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://glycob.oxfordjournals.org/en_US
dc.relation.ispartofGlycobiologyen_US
dc.subject.meshAnticoagulants - Pharmacologyen_US
dc.subject.meshAntithrombins - Chemistry - Pharmacologyen_US
dc.subject.meshChromatography, Gelen_US
dc.subject.meshGlycosaminoglycans - Chemistry - Pharmacologyen_US
dc.subject.meshHeparin - Chemistry - Pharmacologyen_US
dc.subject.meshMolecular Structureen_US
dc.subject.meshOligosaccharides - Chemistryen_US
dc.subject.meshOsmolar Concentrationen_US
dc.subject.meshThrombin - Antagonists & Inhibitorsen_US
dc.titleA novel strategy to generate biologically active neo-glycosaminoglycan conjugatesen_US
dc.typeArticleen_US
dc.identifier.emailRong, J: jrong@hku.hken_US
dc.identifier.authorityRong, J=rp00515en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1093/glycob/9.12.1331-
dc.identifier.pmid10561458-
dc.identifier.scopuseid_2-s2.0-0033456287en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033456287&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume9en_US
dc.identifier.issue12en_US
dc.identifier.spage1331en_US
dc.identifier.epage1336en_US
dc.identifier.isiWOS:000084044200006-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridRong, J=7005980047en_US
dc.identifier.scopusauthoridNordling, K=6603000615en_US
dc.identifier.scopusauthoridBjörk, I=7005841773en_US
dc.identifier.scopusauthoridLindahl, U=35473807100en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats